Design of Biopharmaceutical Formulations Accelerated by Machine Learning

被引:47
作者
Narayanan, Harini [1 ]
Dingfelder, Fabian [1 ,2 ]
Morales, Itzel Condado [1 ,2 ]
Patel, Bhargav [1 ]
Heding, Kristine Enemaerke [2 ]
Bjelke, Jais Rose [3 ]
Egebjerg, Thomas [4 ]
Butte, Alessandro [5 ]
Sokolov, Michael [5 ]
Lorenzen, Nikolai [2 ]
Arosio, Paolo [1 ]
机构
[1] Swiss Fed Inst Technol, Dept Chem & Appl Biosci, Inst Chem & Bioengn, CH-8093 Zurich, Switzerland
[2] Novo Nordisk AS, Dept Biophys & Injectable Formulat, Global Res Technol, DK-2760 Malov, Denmark
[3] Novo Nordisk AS, Dept Purificat Technol, Global Res Technol, DK-2760 Malov, Denmark
[4] Novo Nordisk AS, Dept Mammalian Express, Global Res Technol, DK-2760 Malov, Denmark
[5] DataHow AG, CH-8600 Dubendorf, Switzerland
关键词
formulation; machine learning; artificial intelligence; biopharmaceuticals; antibodies; developability; stability; Bayesian optimization; CONFORMATIONAL STABILITY; MONOCLONAL-ANTIBODY; PROTEIN; DEVELOPABILITY; INSTABILITY; EXCIPIENTS; DYNAMICS; STORAGE;
D O I
10.1021/acs.molpharmaceut.1c00469
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
In addition to activity, successful biological drugs must exhibit a series of suitable developability properties, which depend on both protein sequence and buffer composition. In the context of this high-dimensional optimization problem, advanced algorithms from the domain of machine learning are highly beneficial in complementing analytical screening and rational design. Here, we propose a Bayesian optimization algorithm to accelerate the design of biopharmaceutical formulations. We demonstrate the power of this approach by identifying the formulation that optimizes the thermal stability of three tandem single-chain Fv variants within 25 experiments, a number which is less than one-third of the experiments that would be required by a classical DoE method and several orders of magnitude smaller compared to detailed experimental analysis of full combinatorial space. We further show the advantage of this method over conventional approaches to efficiently transfer historical information as prior knowledge for the development of new biologics or when new buffer agents are available. Moreover, we highlight the benefit of our technique in engineering multiple biophysical properties by simultaneously optimizing both thermal and interface stabilities. This optimization minimizes the amount of surfactant in the formulation, which is important to decrease the risks associated with corresponding degradation processes. Overall, this method can provide high speed of converging to optimal conditions, the ability to transfer prior knowledge, and the identification of new nonlinear combinations of excipients. We envision that these features can lead to a considerable acceleration in formulation design and to parallelization of operations during drug development.
引用
收藏
页码:3843 / 3853
页数:11
相关论文
共 67 条
[1]  
Azimi J, 2010, ADV NEURAL INF PROCE, V23, P1
[2]  
Azimi J, 2012, ARXIV12025597
[3]  
Berkenkamp F., 2015, ARXIV160204450
[4]  
Berkenkamp F, 2019, J MACH LEARN RES, V20
[5]  
Brochu E., 2010, CORR
[6]  
Carpenter J., 2002, Rational design of stable protein formulations
[7]   Improved Stability of a Model IgG3 by DoE-Based Evaluation of Buffer Formulations [J].
Chavez, Brittany K. ;
Agarabi, Cyrus D. ;
Read, Erik K. ;
Boyne, Michael T., II ;
Khan, Mansoor A. ;
Brorson, Kurt A. .
BIOMED RESEARCH INTERNATIONAL, 2016, 2016
[8]   Comparison of High-Throughput Biophysical Methods to Identify Stabilizing Excipients for a Model IgG2 Monoclonal Antibody: Conformational Stability and Kinetic Aggregation Measurements [J].
Cheng, Weiqiang ;
Joshi, Sangeeta B. ;
He, Feng ;
Brems, David N. ;
He, Bing ;
Kerwin, Bruce A. ;
Volkin, David B. ;
Middaugh, C. Russell .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 101 (05) :1701-1720
[9]  
Chevalier Clement, 2013, Learning and Intelligent Optimization. 7th International Conference, LION 7. Revised Selected Papers: LNCS 7997, P59, DOI 10.1007/978-3-642-44973-4_7
[10]  
Chi E.Y., 2016, PHARM EXCIPIENTS, P145, DOI [10.1002/9781118992432.ch4, DOI 10.1002/9781118992432.CH4]